- Home
- BKU vs ARQT Comparison
BKU vs ARQT Comparison
Compare BKU & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BKU | ARQT |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.2B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BKU | ARQT |
|---|---|---|
| Price | $42.53 | $24.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $48.45 | $37.00 |
| AVG Volume (30 Days) | 835.6K | ★ 2.4M |
| Earning Date | 10-21-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | 14.61 | ★ 88.79 |
| EPS | ★ 1.79 | 0.03 |
| Revenue | $21,732,000.00 | ★ $376,072,000.00 |
| Revenue This Year | $5.34 | $42.98 |
| Revenue Next Year | $4.99 | $27.75 |
| P/E Ratio | ★ $23.54 | $804.00 |
| Revenue Growth | 7.45 | ★ 91.34 |
| 52 Week Low | $35.10 | $19.30 |
| 52 Week High | $52.11 | $31.77 |
Technical Indicators
Market Signals| Indicator | BKU | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 36.25 | 42.22 |
| Support Level | $41.95 | $22.82 |
| Resistance Level | $48.20 | $24.67 |
| Average True Range (ATR) | 0.81 | 1.27 |
| MACD | -0.02 | -0.25 |
| Stochastic Oscillator | 34.32 | 15.55 |
Price Performance
Historical ComparisonAbout BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses. The company also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products including commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.